perpetuity.

It is made available under a CC-BY-NC 4.0 International license .

- Large parallel screen of saliva and nasopharyngeal swabs in a test center
- setting proofs utility of saliva as alternate specimen for SARS-CoV-2
- **detection by RT-PCR**

1

4

8

19

- 5 Michael Huber<sup>1</sup>, Peter W. Schreiber<sup>2\*</sup>, Thomas Scheier<sup>2\*</sup>, Annette Audigé<sup>1</sup>, Roberto Buonomano<sup>3</sup>,
- Alain Rudiger<sup>4</sup>, Dominique L. Braun<sup>2</sup>, Gerhard Eich<sup>5</sup>, Dagmar Keller<sup>6</sup>, Barbara Hasse<sup>2</sup>, Christoph
- <sup>7</sup> Berger<sup>7</sup>, Amapola Manrique<sup>1</sup>, Huldrych F. Günthard<sup>1,2</sup>, Jürg Böni<sup>1</sup>, Alexandra Trkola<sup>1</sup>\$
- <sup>9</sup> Institute of Medical Virology, University of Zurich, Zurich, Switzerland
- <sup>2</sup> Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and
- University of Zurich, Zurich, Switzerland
- <sup>3</sup> Division of Infectious Diseases and Hospital Hygiene, Spital Limmattal, Schlieren, Switzerland
- <sup>4</sup> Division of Medicine, Spital Limmattal, Schlieren, Switzerland
- <sup>5</sup> Division of Infectious Diseases, Hospital Hygiene and Occupational Medicine, Stadtspital Triemli,
- 15 Zurich, Switzerland
- <sup>6</sup> Emergency Unit, University Hospital Zurich, Zurich, Switzerland
- <sup>7</sup> Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich,
- 18 Zurich, Switzerland.
- \* shared contribution
- <sup>\$</sup> corresponding author
- Key points: Comparison with nasopharyngeal swabs in a large test center-based study shows that
- saliva is a reliable and convenient material for the detection of SARS-CoV-2 by RT-PCR in adults and
- children.

### **Abstract**

26

27

34

35

39

40

46

### **Background**

- A high volume of testing followed by rapid isolation and quarantine measures is critical to the 28
- 29 containment of SARS-CoV-2. RT-PCR of nasopharyngeal swabs (NPS) has been established as
- sensitive gold standard for the detection of SARS-CoV-2 infection. Yet, additional test strategies are 30
- in demand to increase and broaden testing opportunities. As one attractive option, saliva has been 31
- discussed as an alternative to NPS as its collection is simple, non-invasive, suited for children and 32
- amenable for mass- and home-testing. 33

#### Methods

- Here, we report on the outcome of a head-to-head comparison of SARS-CoV-2 detection by RT-PCR 36
- in saliva and nasopharyngeal swab (NPS) of 1187 adults and children reporting to outpatient test 37
- centers and an emergency unit for an initial SARS-CoV-2 screen. 38

### **Results**

- In total, 252 individuals were tested SARS-CoV-2 positive in either NPS or saliva. SARS-CoV-2 RT-41
- PCR results in the two specimens showed a high agreement (Overall Percent Agreement = 98.0%). 42
- Despite lower viral loads in saliva, we observed sensitive detection of SARS-CoV-2 in saliva up to a 43
- threshold of Ct 33 in the corresponding NPS (Positive Percent Agreement = 97.7%). In patients with 44
- Ct above 33 in NPS, agreement rate dropped but still reaches notable 55.9%. 45

#### Conclusion 47

- The comprehensive parallel analysis of NPS and saliva reported here establishes saliva as a reliable 48
- specimen for the detection of SARS-CoV-2 that can be readily added to the diagnostic portfolio to 49
- increase and facilitate testing. 50

Introduction

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69 70

71

72

73

74

75

76

77

78

79

80

81

The current gold standard for the diagnosis of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection relies on the detection by quantitative reverse-transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal swabs. A range of RT-qPCRs methods have been developed and proven highly sensitive, accurate and reliable [1, 2]. Nasopharyngeal swabs (NPS) are considered the optimal material for detection, particularly in early infection [2]. However, viral load in the nasopharynx can wane in later disease stages, while the virus remains detectable in alternate specimen such as bronchoalveolar lavage or sputum, necessitating a validation of diagnostics tests in these specimens [3-5]. In addition, to overcome limitations in mass screening for early detection of SARS-CoV-2, saliva has been considered as alternate material to NPS [6-10]. NPS collection requires trained personnel while saliva collection is comparatively easy, needs little instruction and is amenable for self-collection. Importantly, saliva collection is non-invasive and it does not create discomfort for the patient. Saliva would thus be of particular advantage for testing children, for whom often parents and pediatricians refrain from testing due to the need to conduct a nasopharyngeal swab. Likewise, the possibility to switch to saliva would also be a relief for adults when frequent testing or large scale screens are required, respectively. Further, considering the current high level of SARS-CoV-2 testing by RT-PCR and antigen tests, which both require nasopharyngeal swabs, shortage in swab supplies may occur. Establishing the possibility to switch to saliva collection in this situation to allow RT-PCR testing to continue is thus highly advisable. Several recent studies have evaluated saliva as alternate specimen [6-29]. While these studies generally agree that detection of SARS-CoV-2 in saliva is possible, comparative analyses came to different conclusions, with some studies noting a better performance of saliva, while others found a substantially lower sensitivity. With few exceptions, patient cohorts tested thus far were in most studies relatively small and often included both hospitalized individuals with advanced SARS-CoV-2 infection as well as outpatients who were newly screened for infection, leaving uncertainty in which situation saliva may be best used. The overall sensitivity and thus utility of saliva in comparison to NPS remains thus differentially debated and needs to be defined. To resolve these issues, we embarked on a large-scale head-to-head comparison of saliva and NPS in a test center setting. The high number of individuals tested (N = 1187) and the high number of positives detected (N = 252), paired with a true-to-life screening in test centers, empowered a highly controlled analysis of agreement and supports the applicability of saliva in routine testing.

### Materials and Methods

Study population 83

- Adults and children (N = 1187) opting for a voluntary SARS-CoV-2 test at one of five participating 84
- test centers were included. Four centers were dedicated test centers for outpatients and one was an 85
- emergency care unit. The study population comprised individuals with SARS-CoV-2 related 86
- symptoms based on Swiss testing criteria and asymptomatic individuals with relevant exposure to a 87
- SARS-CoV-2 index case. Hospitalized patients were not included. Individuals were included without 88
- further selection to avoid skewing. Information on symptomatic or asymptomatic status was collected 89
- as part of the regular procedure for SARS-COV-2 testing and reporting based on self-evaluation 90
- (asymptomatic/mild/strong) by the participants, as they did not see a physician in the test center 91
- setting. 92
- Ethical approval 93
- The Zurich Cantonal Ethics Commission waived the necessity for a formal ethical evaluation based on 94
- the Swiss law on research on human subjects, as the collection of saliva in parallel to a scheduled 95
- nasopharyngeal swab induces no risk and no additional personal data beyond the usual information on 96
- symptoms and duration required by the FOPH for all SARS-CoV-2 tests in Switzerland was collected 97
- (Req-2020-00398). Due to the ethics waiver no informed consent had to be collected. 98
- Sample collection 99
- Test centers were advised to use their regular swab and virus transport medium (VTM)/universal 100
- transport medium (UTM) for nasopharyngeal sampling. Transport media used by the centers included 101
- Cobas PCR Medium (Roche), Liquid amies preservation medium (Copan), Virus Preservative 102
- Medium (Improviral), and in-house VTM (HEPES, DMEM, FCS, antibiotics, antimycotics). 103
- Collection kits for saliva were supplied to the test centers: one tube for saliva collection (Sarsted 104
- 105 62.555.001) and a separate tube with 3 ml VTM (Axonlab AL0607). The procedure for saliva
- collection was described in an instruction leaflet (Figure 1). In Study Arm 1, "Basic", individuals were 106
- asked to clear the throat thoroughly and collect saliva one or two times into the same tube (N = 835). 107
- As a guidance for the volume of saliva to be sampled, participants were instructed by study teams to 108
- collect 0.5 1 ml (approx. a teaspoon full). To investigate a possible influence on SARS-CoV-2 109
- detection in saliva through differences in saliva collection, a subset of patients (N = 352) in Study Arm 110
- 2, "Enhanced", was asked to clear their throat three times thoroughly and collect saliva into the same 111
- tube. Emphasis in this study arm was on enhanced throat clearing to ascertain sampling material from 112
- the posterior oropharynx. Immediately after saliva collection, VTM was added to the crude saliva and 113
- the content mixed through gentle twisting. Saliva was collected directly after NPS and both specimens 114
- immediately sent for SARS-CoV-2 RT-PCR testing. 115

Quantitative SARS-CoV-2 PCR 116

- NPS and Saliva were processed identically using the procedures established for NPS in the diagnostics 117
- laboratory of the Institute of Medical Virology. 500 ul of NPS or saliva in VTM were diluted in 500 ul 118
- of Nuclisens easyMAG Lysis Buffer (BioMérieux), centrifuged (2000 rpm, 5 min) and analyzed with 119
- the Cobas SARS-CoV-2 IVD test (Roche) on a Cobas 6800. All testing for NPS and saliva was done 120
- in parallel on the same day. SARS-CoV-2 detection was further quantified using SARS-CoV-2 121
- Frankfurt 1 RNA as calibrator (European Virus Archive, 004N-02005) allowing to report both Ct and 122
- genome equivalents. 123
- Verification by in-house SARS-CoV-2 E-gene and GAPDH PCR 124
- Discordant results of the Cobas SARS-CoV-2 test between NPS and saliva were re-analyzed using an 125
- in-house RT-qPCR targeting the E-gen based on Corman et al. [1]. GAPDH was measured as input 126
- control as described [30]. Both assays used AgPath-ID One-Step RT-PCR chemistry (Ambion, 127
- ThermoFisher). 128
- Data analysis 129
- E-gene Ct values were used for comparison. If E-gene reported negative but ORF1 reported positive 130
- by the Cobas SARS-CoV-2 IVD test, the ORF1 result was considered and the respective sample rated 131
- positive for SARS-CoV-2. This was the case for one saliva sample. 132
- Data was analyzed using R (version 4.0.2) [31]. 95% confidence intervals were calculated with the 133
- epiR package (version 1.0.15). Method comparison and regression analysis (Passing-Bablok 134
- Regression [32] and Bland-Altman Plot [33]) was performed with the mcr package (version 1.2.1). 135

## Results

- Head-to-head comparison of saliva and nasopharyngeal swabs as material for SARS-CoV-2 detection 137
- by RT-PCR 138
- In our protocol we advised participants to collect approx. 0.5 ml saliva into a wide (30 ml, 30 mm 139
- diameter) tube (Figure 1). Initial attempts in a pilot experiment with smaller tubes (15 ml, 17 mm 140
- diameter) showed that spitting into narrower tubes is problematic for some participants, leading to a 141
- contamination of the outside of the tube with saliva in some cases. Sampling with the wider tubes was 142
- in contrast unproblematic and thus deemed safe. Saliva sampling in children was found equally 143
- unproblematic, children were collaborating and able to expectorate. 144
- Our study included five different test sites to ensure that data are not skewed due to specific 145
- procedures at one site. In Study Arm "Basic" (N = 835) saliva sampling was done with one-time throat 146
- clearing followed by expectorating saliva one to two times. In Study Arm "Enhanced" (N = 352) 147
- participants cleared their throat 3x times followed by spitting. Saliva was mixed with VTM 148

- immediately after collection. The thus diluted material was unproblematic for further processing in the 149 laboratory, no complications in pipetting or invalid results due to the intrinsic viscosity of saliva or 150 congealing were observed. 151 High positive predictive agreement of SARS-CoV-2 detection in saliva and nasopharyngeal swabs
- 152 Adults and children that qualified for a regular SARS-CoV-2 test according to the FOPH and reported 153 to one of the participating test centers or emergency units were enrolled from October 20, 2020 to 154 November 4, 2020. In total 1187 individuals (male 54.8%/female 45.2%) were included (Table1). 155 Median age was 35 with an age range of 5 - 98 years. 89 participants were under the age of 18. The 156 majority of participants were symptomatic 71.9%. Median Days of symptoms ranged from 1 to 30 157 with a median of 2 days. The overall daily positivity rate of SARS-CoV-2 tests by RT-PCR during the 158 study period at our diagnostics unit ranged between 14% and 22%. The positivity rate amongst study 159 participants was 21%. 160 Across both study arms NPS and saliva results showed a high overall percent agreement (OPA = 98%) 161
- and good positive percent agreement (PPA = 91.9%, Table 2 and 3). In only 24 cases discordant 162 results were observed, with 20 saliva samples and 4 NPS showing a negative results when the other 163 specimen tested positive (Figure 2, Table 2). To investigate if discordant results are due to inadequate 164 sampling, detection problems in the RT-PCR, or reflect true negatives in the respective sample 165 material, all discordant pairs were retested using an in-house RT-PCR for the E-gene in conjunction 166 with a GAPDH measurement to control for input. Mean levels for GAPDH input were Ct = 24.6 (SD 167 = 2.7) for NPS and Ct = 24.7 (SD = 2.1) for saliva. One false-negative saliva sample (E-gene Ct 19.7) 168 in NPS) did not contain any material (GAPDH Ct > 40). Excluding this sample, the PPA in the NPS 169 Ct 15 – 20 range reaches 100% (Table 4). 170
- Re-assessment with an in-house E-gene PCR confirmed all discordant results. For one case with a 171 negative NPS, a second swab was collected the following day. This sample showed a high viral load, 172 confirming an unsuccessful swab collection the day earlier. 173
- Of note, in our head-to-head comparison both NPS (N = 1) and saliva (N = 5; N = 4) excluding the 174 sample that did not contain saliva) produced false-negative results in cases where the other specimen 175 showed a high viral load (Ct < 30) highlighting variability in collection for both specimens. 176
- SARS-CoV-2 loads in saliva and nasopharyngeal swab correlate 177
- Correlation analysis of sample pairs that both tested positive (N = 228) confirmed that saliva and NPS 178 results are in good agreement (Figure 3A). Notably, Ct values in saliva were on average 4.79 higher 179 than the corresponding Ct in NPS. This corresponds to a factor 28 lower viral load (Figure 3B). 180 Notably though, at high Ct values, this difference was less pronounced possibly adding to the high 181
- PPA of detection in saliva at low viral load in the corresponding NPS. 182

Detection of SARS-CoV-2 in saliva from symptomatic and asymptomatic individuals

Our study recorded severity of symptoms (asymptomatic/mild/strong) at the sampling time point by self-evaluation (Figure 4A). We observed a good positive percent agreement of saliva and NPS in symptomatic individuals (PPA = 92.3%). In line with a trend to lower viral loads, i.e. higher Ct values in absence of symptoms (asymptomatic median Ct 28.4; mild symptoms median Ct 23.7; strong symptoms median Ct 21.6), the PPA was lower in asymptomatic participants (PPA = 84.2%). We observed decreasing viral loads with ongoing symptomatic infection in both saliva and NPS, highlighting a transient window of detection in the upper respiratory tract. Interestingly, changes in saliva were overall less dynamic than in NPS (Figure 4B).

192 Intensified throat clearing with saliva collection is favorable

To investigate if the intensity of saliva collection has an impact, we analyzed the two study arms of saliva collection separately. Participants were either asked to clear the throat thoroughly ("Basic", N = 835) or in an intensified protocol to clear it three times ("Enhanced", N = 352) and collect about 0.5 – 1 ml of saliva. We found that intensified saliva collection appears favorable for samples with low viral load. With the enhanced sampling protocol, PPA with NPS of ct >33 reached 66.7% (CI 35% - 90%), compared to 50.0% (CI 28% - 72%) with the basic protocol (Figure 5 and Table 5). Differences were, however, not statically significant, highlighting robust detection of SARS-CoV-2 in saliva in the two collection procedures tested.

### Discussion

In the present study we sought to devise and evaluate a saliva sampling strategy that provides i)
representative sampling of virus containing material, ii) easy and safe sampling in adults and children,

204 iii) possibility for home collection, iv) straight forward processing in the laboratory.

We opted for a saliva collection procedure where participants clear their throat to first generate saliva from the back of the throat and then expectorate the saliva into an empty container. We considered clearing the throat important to sample material from the posterior oropharynx where SARS-CoV-2 sampling by oropharyngeal swabs is known to be efficient [34, 35]. While gargling with saline or buffer solutions has been suggested as a possibility to sample saliva from the deep throat [36, 37], we rated this procedure as less operable as the gargling solution would need to be optimized for taste to be accepted by individuals, could not include preservatives, and gargling itself may potentially generate aerosols. In addition, gargling is not practicable for many smaller children for whom we in particular sought to create increased possibilities for SARS-CoV-2 testing as NPS collection for children is often not practical.

Our study demonstrates an excellent agreement of saliva in the head-to-head comparison with NPS and thus recommends saliva as alternate material for SARS-CoV-2 detection by RT-PCR. Up to a Ct 33 (equivalent to approximately 26'000 genome copies/ml) in the corresponding NPS, a notably high

PPA (97.6%) is reached. Of note, virus loads in an even lower range are considered to impose a marginal risk for transmission as suggested by contact tracing and in vitro culturing studies [38-40]. Considering the observed PPA in detection, saliva may safely be envisaged as substitute for NPS detection in a range of settings. Possible scenarios include i) sampling of children, ii) home collection in quarantine, iii) test centers without trained medical personnel (e.g. schools, universities, companies), iv) non-irritating alternative for persons that need frequent testing due to their occupation or health status, v) fast large-scale screens in institutions (e.g. elderly homes). In situations where besides SARS-CoV-2 other respiratory viruses, e.g., Influenza and RSV, need to be excluded, NPS should, however, remain the standard material of choice as it allows rapid detection with multiplex-PCR from a single specimen. In addition, if SARS-CoV-2 infection has to be ruled out with highest possible sensitivity (e.g. in transplantation), NPS should remain the standard procedure. The majority of SARS-CoV-2 in saliva represents likely virus secreted from infected cells in the nasopharynx and is not locally produced. Collecting material from the posterior oropharynx is thus important. This is also highlighted in our study as the collection protocol with intensified throat clearing shows a trend to increased PPA at low viral loads. It remains possible that eating or drinking shortly before collection may decrease viral content in the oral cavity and throat. In the present study, neither eating, drinking nor smoking was controlled as study subjects came for an elective analysis by NPS and thus could only be informed about the saliva sampling on site immediately before the collection. Abstaining from food and beverage uptake shortly (1h) before saliva collection could be considered in forth-coming applications of saliva as test material, as it may increase the efficacy of SARS-CoV-2 detection in saliva even further. In summary, our analysis rates saliva as valid alternate specimen for SARS-CoV-2 detection by RT-PCR. Saliva collection is non-invasive, thus not strenuous for patients, does not need trained personnel, allows collection at any location, and allows self-collection. Importantly, as we show here, saliva collection does not require any adjustments in the diagnostics tests; established RT-qPCR can be used. Combined with the high reliability in detecting SARS-CoV-2 infection as demonstrated in our head-to-head comparison with the standard NPS, increasing and facilitating test efforts by monitoring SARS-CoV-2 infection in saliva is rapidly attainable and needs to be considered.

### **Acknowledgments**

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247 248

249

We thank Martin Ringer and the staff of the participating test centers for coordinating the sample collection, the staff of the Institute of Medical Virology diagnostics unit, sample triage and administration for their support and Urs Karrer and Alexander Wepf for helpful discussions.

# **Funding**

publish, or preparation of the manuscript.

250

254

This work was supported by grants of the Swiss federal office of public health (FOPH) and the 251 University of Zurich Foundation to A.T. Roche Diagnostics supported the study with PCR kits and 252 consumables. The funders had no role in study design, data collection and analysis, decision to 253

### References

- Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by 1. 256 real-time RT-PCR. 2020; 25(3). 257
- WHO. Target product profiles for priority diagnostics to support response to the COVID-19 2. 258 pandemic v.1.0. Geneva, 2020 Sep 29. 259
- 3. Weiss A, Jellingsø M, Sommer MOA. Spatial and temporal dynamics of SARS-CoV-2 in 260 COVID-19 patients: A systematic review and meta-analysis. EBioMedicine 2020; 58: 102916. 261
- He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of 4. 262 COVID-19. Nat Med 2020; 26(5): 672-5. 263
- Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with increased 5. 264 disease severity and mortality. Nature communications 2020; 11(1): 5493. 265
- 6. Berenger BM, Conly JM, Fonseca K, et al. Saliva collected in universal transport media is an 266 effective, simple and high-volume amenable method to detect SARS-CoV-2. Clin Microbiol 267 Infect 2020. 268
- Chen JH, Yip CC, Poon RW, et al. Evaluating the use of posterior oropharyngeal saliva in a 7. 269 point-of-care assay for the detection of SARS-CoV-2. Emerging microbes & infections 2020; 270 9(1): 1356-9. 271
- Moreno-Contreras J, Espinoza MA, Sandoval-Jaime C, et al. Saliva Sampling and Its Direct 272 8. Lysis, an Excellent Option To Increase the Number of SARS-CoV-2 Diagnostic Tests in 273 Settings with Supply Shortages. J Clin Microbiol 2020; 58(10). 274
- 9. Valentine-Graves M, Hall E, Guest JL, et al. At-home self-collection of saliva, oropharyngeal 2.75 swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: Post-collection 276 acceptability of specimen collection process and patient confidence in specimens. PloS one 277 **2020**; 15(8): e0236775. 278
- 10. Yokota I, Shane PY, Okada K, et al. Mass screening of asymptomatic persons for SARS-CoV-279 2 using saliva. Clinical infectious diseases : an official publication of the Infectious Diseases 280 Society of America 2020: ciaa1388. 281
- Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect SARS-CoV-2. The 11. 282 Journal of infection **2020**; 81(1): e45-e50. 283
- Fakheran O, Dehghannejad M, Khademi A. Saliva as a diagnostic specimen for detection of 12. 284 SARS-CoV-2 in suspected patients: a scoping review. Infectious diseases of poverty 2020; 285 9(1): 100. 286
- Iwasaki S, Fujisawa S, Nakakubo S, et al. Comparison of SARS-CoV-2 detection in 13. 287 nasopharyngeal swab and saliva. The Journal of infection 2020; 81(2): e145-e7. 288
- 14. Iwata K, Yoshimura K. A concern regarding estimated sensitivities and specificities of 289 nasopharyngeal and saliva specimens for SARS-CoV-2 infection. Clinical infectious diseases: 290 an official publication of the Infectious Diseases Society of America 2020. 291
- 15. Jamal AJ, Mozafarihashjin M, Coomes E, et al. Sensitivity of nasopharyngeal swabs and 292 saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 293 Clinical infectious diseases: an official publication of the Infectious Diseases Society of 294 America 2020. 295
- Lai CKC, Chen Z, Lui G, et al. Prospective study comparing deep-throat saliva with other 16. 296 respiratory tract specimens in the diagnosis of novel coronavirus disease (COVID-19). The 297 Journal of infectious diseases 2020. 298
- Landry ML, Criscuolo J, Peaper DR. Challenges in use of saliva for detection of SARS CoV-2 17. 299 RNA in symptomatic outpatients. Journal of clinical virology: the official publication of the 300 Pan American Society for Clinical Virology 2020; 130: 104567. 301
- Leung EC, Chow VC, Lee MK, Lai RW. Deep throat saliva as an alternative diagnostic 18. 302 specimen type for the detection of SARS-CoV-2. J Med Virol 2020. 303
- 19. McCormick-Baw C, Morgan K, Gaffney D, et al. Saliva as an Alternate Specimen Source for 304 Detection of SARS-CoV-2 in Symptomatic Patients Using Cepheid Xpert Xpress SARS-CoV-305 2. Journal of clinical microbiology 2020; 58(8). 306
- Migueres M, Mengelle C, Dimeglio C, et al. Saliva sampling for diagnosing SARS-CoV-2 20. 307 infections in symptomatic patients and asymptomatic carriers. Journal of clinical virology: the 308 official publication of the Pan American Society for Clinical Virology 2020; 130: 104580. 309

- 21. Pasomsub E, Watcharananan SP, Boonyawat K, et al. Saliva sample as a non-invasive 310 specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. Clin 311 Microbiol Infect 2020. 312
- Procop GW, Shrestha NK, Vogel S, et al. A Direct Comparison of Enhanced Saliva to 22. 313 Nasopharyngeal Swab for the Detection of SARS-CoV-2 in Symptomatic Patients. J Clin 314 Microbiol 2020; 58(11). 315
- 23. Rao M, Rashid FA, Sabri F, et al. Comparing nasopharyngeal swab and early morning saliva 316 for the identification of SARS-CoV-2. Clinical infectious diseases: an official publication of 317 318 the Infectious Diseases Society of America 2020.
- 24. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in 319 saliva. Clinical infectious diseases: an official publication of the Infectious Diseases Society 320 of America 2020. 321
- To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior 25. 322 oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-323 2: an observational cohort study. The Lancet Infectious diseases **2020**; 20(5): 565-74. 324
- 26. Uwamino Y, Nagata M, Aoki W, et al. Accuracy and stability of saliva as a sample for reverse 325 transcription PCR detection of SARS-CoV-2. Journal of clinical pathology 2020. 326
- 27. Williams E, Bond K, Zhang B, Putland M, Williamson DA. Saliva as a Noninvasive 327 Specimen for Detection of SARS-CoV-2. Journal of clinical microbiology 2020; 58(8). 328
- 28. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or Nasopharyngeal Swab 329 Specimens for Detection of SARS-CoV-2. N Engl J Med 2020; 383(13): NEJMc2016359-330 1286. 331
- 29. Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. 332 The Journal of infection **2020**; 81(3): e48-e50. 333
- 30. Cohrs RJ, Randall J, Smith J, et al. Analysis of individual human trigeminal ganglia for latent 334 herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR. 335 Journal of Virology **2000**; 74(24): 11464-71. 336
- Team RDC. R: A language and environment for statistical computing: R Foundation for 31. 337 Statistical Computing, Vienna, Austria, 2005. 338
- Passing H, Bablok. A new biometrical procedure for testing the equality of measurements 32. 339 from two different analytical methods. Application of linear regression procedures for method 340 comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983; 21(11): 709-341 342
- 33. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of 343 clinical measurement. The Lancet 1986; 1(8476): 307-10. 344
- Patel MR, Carroll D, Ussery E, et al. Performance of Oropharyngeal Swab Testing Compared 34. 345 With Nasopharyngeal Swab Testing for Diagnosis of Coronavirus Disease 2019—United 346 States, January 2020–February 2020. Clinical Infectious Diseases 2020. 347
- 35. Calame A, Mazza L, Renzoni A, Kaiser L, Schibler M. Sensitivity of nasopharyngeal, 348 oropharyngeal, and nasal wash specimens for SARS-CoV-2 detection in the setting of 349 sampling device shortage. European Journal of Clinical Microbiology & Infectious Diseases 350 2020. 351
- 36. Malecki M, Lüsebrink J, Teves S, Wendel AF. Pharynx gargle samples are suitable for SARS-352 CoV-2 diagnostic use and save personal protective equipment and swabs. Infect Control Hosp 353 Epidemiol **2020**: 1-2. 354
- Goldfarb DM, Tilley P, Al-Rawahi GN, et al. Self-collected Saline Gargle Samples as an 37. 355 Alternative to Healthcare Worker Collected Nasopharyngeal Swabs for COVID-19 Diagnosis 356 in Outpatients. medRxiv: the preprint server for health sciences 2020: 2020.09.13.20188334. 357
- 38. Busnadiego I, Fernbach S, Pohl MO, et al. Antiviral Activity of Type I, II, and III Interferons 358 Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. mBio 2020; 11(5). 359
- 39. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. 360 Clinical infectious diseases: an official publication of the Infectious Diseases Society of 361 America 2020. 362
- 40. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients 363 with COVID-2019. Nature **2020**; 581(7809): 465-9. 364

# **Tables**

366

367

368 369

370

371

373

374

### Table 1: Participant demographics

Total	1187
Male/Female (%)	650 (54.8%)/537 (45.2%)
Age median (range)	35 (5 – 98)
Symptomatic mild (%)	764 (64.4%)
Symptomatic strong (%)	89 (7.5%)
Asymptomatic (%)	291 (24.5%)
No information on symptoms (%)	43 (3.6%)
Median days of symptoms (range)	2 (1 – 30)

### Table 2: Contingency table full cohort

	NPS positive	NPS negative	Total
Saliva positive	228	4	232
Saliva negative	20	935	955
Total	248	939	1187

#### Table 3: Agreement and Predictive Values 372

Saliva and NPS Agreement and Predictive Values (reference standard NPS, 95% CI)						
Positive Percent Agreement (PPA)	91.9% (87.8% - 95.0%)					
Negative Percent Agreement (NPA)	99.6% (98.9% - 99.8%)					
Overall Percent Agreement (OPA)	98.0% (97.0% - 98.7%)					

### Table 4: Positive Percent Agreement (PPA) stratified by NPS E-gene Ct-values

NPS (Ct)	>10-15	>15-20	>20-25	>25-30	>30-33	>33-35	>35-40
NPS positive	1	54	90	56	13	13	21
Saliva false negative	0	1 (0*)	2	2	0	5	10
PPA	100%	98.1% (100%*)	97.8%	96.4%	100%	61.5%	52.4%
*Excluding one sample that did not contain saliva as defined by GAPDH measurement.							

Table 5: Positive Percent Agreement (PPA) stratified by NPS E-gene Ct-values and saliva sampling

	Full cohort (N = 1187)			Ва	Basic Sampling (N = 835)			Enhanced Sampling (N = 352)		
NPS (Ct)	all	>10-33	>33-40	all	>10-33	>33-40	all	>10-33	>33-40	
NPS positive	248	214	34	183	161	22	65	53	12	
Saliva false negative	20	5	15	16	5	11	4	0	4	
PPA	91.9%	97.7%	55.9%	91.3%	96.9%	50.0%	93.8%	100%	66.7%	

# **Figures**

377

378

379 380

381

382 383


384


385

386

387 388 Figure 1: Instruction leaflet for saliva collection

Participants were asked to clear the throat and collect saliva into a collection tube (A). VTM was added to the crude saliva immediately after collection (B), and the content was mixed through gentle twisting (C).








Figure 2: High agreement of SARS-CoV-2 detection in saliva and nasopharyngeal swabs Summary of the full cohort (N = 1187 study participants). Roche Cobas E-Gene Ct values of paired NPS and saliva samples are depicted. neg = PCR negative; red dashed line equals identity.




Figure 3: SARS-CoV-2 levels in saliva and nasopharyngeal swabs correlate

390

391

392

393

395

A) Passing-Bablok Regression of E-gene Ct-values of NPS and saliva of all positive pairs from the full cohort (N = 228; p < 0.0001). Red dashed line equals identity, blue line shows linear trend.

B) Bland-Altmann Plot of E-gene Ct-values of NPS and saliva of all positive pairs from the full cohort (N = 228).





Figure 4: Viral loads in NPS and saliva decrease with ongoing infection

396

- A) E-gene Ct-values of NPS and saliva of all positive pairs from the full cohort (N = 226). 397
- B) Duration of symptoms in symptomatic patients (N = 836) versus E-gene Ct value in saliva and 398
- NPS. neg = PCR negative, red dashed line equals identity, blue line shows linear trend. 399



- Figure 5: Intensified saliva sampling increases low level SARS-COV-2 detection in saliva. 401
- E-gene Ct values of paired NPS and saliva samples of study arm "Basic" (1-2x saliva per tube; N = 402
- 835) and "Enhanced" saliva collection (3x saliva per tube; N = 352). 403

